The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
_256_384.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Heart failure affects an estimated 64.3 million people worldwide
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
Subscribe To Our Newsletter & Stay Updated
